Completed PHASE1 INTERVENTIONAL 2-arm NCT02069704

Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients

Open Label Randomized Bioequivalence Study to Evaluate the Pharmacokinetic and Safety Profile of Bevacizumab Biosimilar (BEVZ92) vs Bevacizumab (AVASTIN®), Both With FOLFOX or FOLFIRI, in First-line Treatment for mCRC Patients

Sponsor: Laboratorio Elea Phoenix S.A.

Conditions Metastatic Colorectal Cancer (mCRC)

Interventions Avastin® (bevacizumab, reference product) Bevacizumab biosimilar (BEVZ92)

Updated 14 times since 2017 Last updated: Jul 19, 2019 Started: Oct 29, 2014 Primary completion: Oct 31, 2015 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Metastatic Colorectal Cancer (mCRC), this trial is completed. The trial is conducted by Laboratorio Elea Phoenix S.A. and has accumulated 14 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

14 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1

▶ Show 9 earlier versions

Oct 2022 — Dec 2022 [monthly]

Completed PHASE1
Jan 2021 — Oct 2022 [monthly]

Completed PHASE1
May 2020 — Jan 2021 [monthly]

Completed PHASE1
Aug 2019 — May 2020 [monthly]

Completed PHASE1
Jun 2018 — Aug 2019 [monthly]

Completed PHASE1
May 2018 — Jun 2018 [monthly]

Completed PHASE1
Mar 2018 — May 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Oct 2017 — Mar 2018 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Laboratorio Elea Phoenix S.A.
Libbs Farmacêutica LTDA
mAbxience Research S.L.

Data source: mAbxience Research S.L.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barretos, Brazil , Buenos Aires, Argentina , Chennai, India , Dnipropetrovsk, Ukraine , Ijuí, Brazil , Karamsad, India , Kharkiv, Ukraine , Lviv, Ukraine , Madrid, Spain , Mumbai, India and 6 more locations